Innate immunity and inflammation play key roles in a wide range of pathology -including heart disease and vasculopathies. Current thinking suggests "damage" rather than "foreignness" as the actual trigger of the immune system, which has caused a dramatic change in how we tend to view the etiopathology of most types of heart disease. The future potential of certain anti-inflammatory therapeutic strategies in addressing heart disease is intriguing. Still, the Janus face of immunity/inflammation cannot be over emphasized as adverse manipulation of these systems may prove ineffectual or worse, damaging. Knowledge on functional characteristics of individual immune mediators is undoubtedly a central theme, but in depth understanding of the multiple biological actions of these molecules, as well as their contextual function, is the corner stone in deciding on potential future targets for pharmacologic manipulation. Animal models of human heart disease are currently being investigated and clinical trials conducted to gain further knowledge in this essential area of cardiovascular research, but the scarcity of cardiovascular research focusing on signaling molecules and pathways of innate immunity is still evident. Genomic and proteomic research in heart disease is going through its formative years, and much is still unknown about the complex pathway dynamics utilized by the innate immune system. This review will provide an overview of the current literature focusing on innate immunity and the heart, and hopefully will spark an interest in further basic as well as clinical research. As more information on cardiovascular immunity becomes available, this will provide a better understanding and thus act as the foundation for potential development of new treatment strategies for treatment of cardiovascular disorders.
Innate immunity and inflammation in heart disease
Virtually all organisms live under constant exposure to a variety of infectious as well as non-infectious environmental microorganisms. External and internal surfaces, including the cutaneous epithelia and the mucosal linings constitute an immediate and proficient barrier towards potential pathogens [1] . The vast majority of microorganisms that succeeds in passing this first-line-of intrinsic defense will be eliminated by an array of other defense mechanisms of the innate immune response, including accumulation of macrophages and phagocytic neutrophils at the infection site [1] . In addition to this cellular innate immune response, plasma proteins, including complement components, join at the site of infection, constituting humoral innate immunity [1] . Modern perspectives recognize inflammation as a reaction involved in a variety of diseases including those of non-pathogenic (i.e. without microbial involvement) origin [2] . A key feature of inflammation in non-pathogenic disease is the more recent recognition that sentinel cells of all tissues can elicit as well as participate in the inflammatory response along with classically circulating leukocytes and cells of the lymphoid organs [2] . Classically, the term sentinel cells has been used in reference to dendritic cells Cardiovascular Research 73 (2007) 26 -36 www.elsevier.com/locate/cardiores qua their localization along the major routes of entry for microorganisms and their capacity to link innate and adaptive immune responses [3, 4] . Recently, however, the term "sentinel" has been applied more widely to include different cell types which continuously sense the environment and produce mediators which may act to either activate or silence particular immune functions [5] [6] [7] [8] . As such, sentinel cells can thus also include endothelial cells, cardiomyocytes, fibroblasts and mast cells (which are found copiously in the heart) [2] . The endothelium in particular figures prominently in any consideration of the role of inflammation as endothelial cells are now recognized for their ability to switch from an antiinflammatory function into a pro-inflammatory mode [2] ; just as inflammation at large has been analogized with a "Janus Face" -qua its capacity to heal as well as destroy [2] . Inflammation is a fundamental reaction instigated against virtually all injury types. Not surprisingly many forms of cardiovascular diseases therefore involve cells and mediators of the inflammatory system [2] . Even though cardiomyocytes do not fall within the category of traditional immune cells, they do respond to injury by producing some of the mediators (including different cytokines) that are classically associated with cells of the innate immune system [9] . The innate immune response, including inflammation, may therefore play an important role -on a local as well as systemic level -in a range of heart diseases that were not traditionally considered immunologic in etiology. Mediators of an innate immune and inflammatory response affect the cardiovascular system: 1) through direct immune and inflammatory reactions within the heart; including pathology such as cardiac remodeling, heart failure, ischemia and reperfusion injury, and 2) by constituting a central role in atherosclerosis and other types of vascular diseases; a role which has been reported in recent reviews [10, 11] . Adding to the outlined local innate response mechanisms within the myocardium comes an activation of the immune system on a systemic level, as is seen in chronic heart failure patients with increased levels of pro-inflammatory cytokines in both plasma as well as the failing myocardium [12, 13] . As such, the resulting overall innate immune response defending the heart against any given danger is therefore likely an orchestration between "non-immune derived" mediators operating within the myocardium as an "immediate first-lineof-defense" and a systemic reaction including recruitment of traditional bone marrow derived professional immune cells.
Toll-like receptors are expressed in the heart
Toll-like receptors (TLRs) are classic pattern recognition receptors (PRRs), which are gene-encoded proteins used by the innate immune system to recognize largely invariant pathogen-associated molecular patterns (PAMPs) that are shared by pathogen groups, but at the same time not present in the host [14] . Examples of PAMPs are lipopolysaccharides of bacteria and double-stranded RNA of different viruses [14] . TLRs are characterized by an extracellular leucine-rich repeat domain and a cytoplasmatic toll/interleukin-1 receptor homology domain (TIR). Thirteen different transmembrane proteins of the TLR family have been identified so far, with a number of specific ligands associated whose binding result in activation and transcription of appropriate host-defense genes [15] . Virtually all cells of the heart express TLRs [16] . TLR-2 to -4, and TLR-6 are readily detectable in cardiomyocytes, while TLR-1 to TLR-6 are found in endotheliocytes, smooth muscle cells and macrophages of the vasculature [16] . The ligands for TLR-2, -3, -4 and TLR-9 are the most wellcharacterized to date. A variety of pathogens, including different bacteria and yeast, is recognizable by TLR-2, whereas TLR-3 is the PRR for viral double-stranded RNA [17] . The first mammalian TLR described was TLR-4, and hence this is the best described receptor of the family [18] . TLR-4 is the PRR for LPS, which is the major component of the outermembrane of Gram-negative bacteria and a compound that can induce a robust increase in the pro-inflammatory cytokines TNF-α and IL-1β within the myocardium ( Fig. 1 Immediate Effects) [19] . In addition, TLR-4 recognizes a variety of PAMPs from other invading pathogens as well as additional non-pathogenic ligands, including some chemotherapeutic agents [19] . TLRs can set off a complete immune response including innate immune activity through macrophages activated by induction of pro-inflammatory cytokines and antimicrobial molecules (e.g. nitric oxide), which enables macrophages to fight invading pathogens, as well as an adaptive immune response by activating dendritic cells, which can stimulate T-cell expansion and differentiation [16] . TLRs are furthermore able to maintain this adaptive immune response by providing the necessary co-stimulatory molecules [16] . The TLR family can initiate an immune response that is both cell and pathogen specific. Members of the TLR system are expressed differentially among immune and parenchymal cells, and many TLRs are activated by more than a single class of PAMPs [16] . In addition, distinct cell signaling pathways are triggered by different TLR classes, such that TLR-2 responses involve IL-8, IL-12 and IL-23 secretion, whereas TLR-4 responses include release of cytokines such as IL-10, IFN-β and IL-12. This allows for some degree of specificity even for the TLR-dependent innate immunity signaling pathways, which permit different immune responses for various PAMPs [16] . In the case of TLR-4, LPS initially binds to LPS binding protein (LBP) which transfers LPS to CD14 ( Fig. 2A) . It has, however, been reported that LPS-induced activation of signal transduction likely occur via a CD-14 independent mechanism in cardiomyocytes [20] , even though CD14 and LBP expression have been reported on cardiomyocytes [20, 21] . Fig. 2A shows the CD14/LBP-dependent LPSmediated NF-κB-signaling via TLR4, since less is known about the specific details of the CD14-independent pathway. Fig. 2B is a schematic of the reported pathways for LPSmediated CD14/LBP-independent signaling in cardiomyocytes [22] . LBP and CD14 are both expressed on the plasma membrane and activate TLR-4 after associating with MD2 [16] . Once activated, signaling continues via the intracytoplasmatic TIR homology domain, following either a "MyD88 dependent" or "MyD88 independent" pathway [23] . The MyD88 dependent route involves recruitment of the cytoplasmic adapter protein MyD88 and IRAK (interleukin receptor associated kinase), which is associated with TOLLIP (toll interacting protein). IRAK consequently becomes autophosphorylated and dissociates from the receptor complex after which TRAF-6 (TNF receptor-associated factor 6) is recruited. This activates downstream kinases including the inhibitory κB kinase complex that directly phosphorylates IκBα leading to nuclear translocation of NF-kB and initiation of gene-transcription ( Fig. 2A) [24] . NF-κB activation is among the bestcharacterized pathways, but studies strongly suggests that several other yet unidentified pathways may exist as well [25] .
3. Nf-κB signaling in the heart NF-κB (nuclear factor kappa-B) was first discovered in 1986 [26] , and found to contain subunit proteins involving Rel-homology domains (i.e. Rel family members), which are well preserved central components of the innate immune response [27] . To date, five mammalian NF-κB subunit Fig. 1 . Different types of myocardial injuries can activate an inherent cardiac stress response, which includes the expression of pro-inflammatory cytokines. The innate stress response plays a central role in instigating and orchestrating homeostatic responses within the heart. The effect of different cytokines upon the heart is depending on factors such as time of exposure and concentration. Abbreviations -RAAS: renin-angiotensin-aldosteron system; AII: angiotensin-2; NF-κb: nuclear factor kappa B; TNF: tumor necrosis factor; MAPK: mitogen-activated protein kinase; MMP: matrix metalloproteinases; TGF-β: tissue growth factor beta; MnSOD: manganese superoxide dismutase; HSPs: heat shock proteins; IL-1β: interleukin-1-beta; IL-6 family: incl. interleukin-6 (IL-6), leukemiainhibitory factor (LIF), cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF), interleukin-11 (IL-11), and oncostatin M (OSM); c-IAP1 and 2: cellular inhibitors of apoptosis 1 and 2; Bcl genes have been identified (RelA, cRel, RelB, NF-κB1, and NF-κB2) and NF-κB exists as dimers of these subunit proteins [27] . NF-κB dimers are complexed to one of seven known members of the IκB (inhibitory kappa-B) family which interacts with the Rel-homology domain of NF-κB [27] . The most common of the IκB proteins are the IκBα and IκBβ which are both expressed in the heart [28] . Contrary to the common perception, evidence indicates that NF-κB and IκBα, as well as components of the upstream signaling cascade, shuttle between the nucleus and the cytoplasm [29] . Thus NF-κB activation may occur via IκB phosphorylation in both compartments ( Fig. 2A ) [29] . The prevailing model dictates that the IκB proteins regulate NF-κB activity by: 1) maintaining equilibrium between the nucleus and the cytoplasm, where NF-κB levels are quite low, in the absence of any stimuli, and 2) inhibition of NF-κB's DNA-binding activity via interaction between NF-κB and the C-terminal PEST 1 domain of IκBα [30] . NF-κB can, however, be activated by two pathways. Degradation of IκB inhibitors leads the way for the so called canonical (NF-κB1) signaling pathway, which is present in the heart [28, 31] . A second non- canonical (NF-κB2) pathway has been described for NF-κB activation, which is based on regulated NF-κB2 processing rather than IκB degradation [32] . The canonical pathway may be activated by an array of signaling cascades including the JAK/STAT pathways [27] . As with many transcription factors phosphorylation increases the transactivational activity of NF-κB. NF-κB is a multi-tasking transcription factor implicated in an array of normal biological phenomena as well as different states of pathology such as cell growth and cell death, atherosclerosis, and innate immunity including inflammation [27] . Activating stimuli, such as cytokines, that result in initiation of transcription of genes which would otherwise remain silent or become transcribed at a very low rate in the responding cell, is a central theme in immunology. NF-κB can be considered a prototype, when discussing transcription factors, since it plays a central role in a number of different immunological reactions. Synthesis of pro-inflammatory cytokines and adhesion molecules is principally mediated by NF-κB, which itself is activated in response to a wide range of stimuli including cytokines, pathogenic microorganisms, viruses, mitogens, oxidative stress and modified LDL [33] . One of the recently identified nucleotide-binding oligomerization domain proteins (aka caspase recruitment domain-containing proteins), Nod1, has also been associated with NF-κB activation, and Nod1 furthermore appears to play a key role in endothelial cell immunity [34] . Nod proteins are implicated in intracellular pattern recognition, and Nod1 and Nod2 mRNA expression have both been identified in the heart [35] . The recently established Nod1 and Nod2 knockout mice will therefore help shed light on the specific role played by these newly identified peptides within the intrinsic cardiac immune system and its potential interaction with other organs [34] . NF-κB signaling in the heart is quite complex, since this factor is positioned as an integrator of diverse signaling pathways at multiple levels [27] . NF-κB activity is normally undetectable in the myocardium, suggesting that it acts predominantly in response to various stimuli to the heart [27] . Activation of NF-κB can tip the normal homeostatic balance of opposing processes in the myocardium, but the precise effect on the cardiac physiology or pathophysiology depends largely on the specific cell type and the set of NF-κB-dependent genes that is activated as well as the immediate environment [27] . The functional ambivalence can be exemplified by the fact that NF-κB activity seems to be involved in angiogenesis after hypoxia [36] , while activation of NF-κB after ischemia/reperfusion has been implicated in a pro-cell death effect [27] . Multiple biological processes can be affected by NF-κB in the heart [37] . NF-κB activates gene expression that affects processes such as cardiomyocyte growth, contractile function and death as well as extracellular matrix remodeling and inflammation ( Fig. 1) [27] . A compendium of all identified NF-κB regulated genes is maintained by courtesy of Dr. Gilmore at Boston University 2 . It is critical to note, that NF-κB regulate genes that are involved in paradoxical responses given that this has profound implications for understanding the role of NF-κB in pathology [27] . Understanding how the output of numerous parallel signaling pathways is integrated by NF-κB (as well as other transcription factors) resulting in gene expression with specific effects on the heart is a fundamental first step towards developing rational molecular therapies to address the injurious while retaining the protective aspects of transcriptional signaling networks activated by NF-κB in different types of cardiovascular disease [27] . Also, NF-κB activation occurs in several different types of cells and organs and may be primarily protective in one location while injurious in another [27] . Consequently, knowledge about NF-κB gene activation from one organ-or cell type cannot be immediately extrapolated to the immunophysiological mechanisms in the heart.
Signaling via the JAK/STAT pathway in the heart
The Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway plays a central role in cardiac pathophysiology, and it is now recognized that a large number of different cytokines exert their effect through binding to receptors that activate this pathway, thus utilizing a rapid and direct route to effect changes in gene expression in the nucleus [1] . The JAK-STAT pathway involves cytokines acting via receptors associated with cytoplasmic Janus kinases (JAKs), which have two symmetrical kinase-like domains and are thus named after the two-headed mythical Roman god Janus [1] . Upon activation, the JAKs phosphorylate the cytosolic "signal transducers and activators of transcription" (STATs) proteins, which lead to their dimerization and translocation to the nucleus where they activate a variety of genes, including those contributing to lymphocyte growth and differentiation and thus adaptive immunity [1] . A range of different JAKs and STATs exists and using different combinations hereof ensures the specificity of signaling in response to different cytokines [1] . Mammals have four members of the JAK family (JAK1-3, and Tyrosine kinase 2 [Tyk2]), and seven members of the STAT family (STAT1-4, STAT5A, STAT5B, and STAT6), which are all expressed in cardiac tissue [38] . The STAT factors can function both as modulators of cytokine signaling and as sensors responding to cellular stress [39] . JAK-STAT signaling has been implicated in pressure overload-induced cardiac hypertrophy and remodeling, ischemic preconditioning and ischemia/reperfusion-induced cardiac dysfunction, while also playing an important role in cytokine signaling in cardiomyocytes (Fig. 1) [40] . Furthermore, the promoter of the prohormone angiotensinogen gene acts as the target site for STAT proteins, thus linking the JAK/STAT pathway to activation of the autocrine angiotensin II loop within the heart [41] . In addition, stress-induced activation of matrix metalloproteinases (MMPs) is mediated by angiotensin II acting via the JAK-STAT pathway [42] . Activation of specific STAT proteins constitutes the primary signaling event in the development of myocardial hypertrophy and ischemia [41] . Angiotensin II has been shown to activate STAT1, 3 and 5 through JAK2 in cardiomyocytes. Despite similar structural organization, STAT1 and STAT3 have opposing effects on the myocardium with STAT1 exhibiting proapoptotic effects while STAT3 is able to protect cardiomyocytes from apoptosis after ischemia/reperfusion [39] . Studies have also shown that STAT5A and STAT6 are activated during ischemia, whereas activation of STAT3 and STAT5A occurs in myocardial hypertrophy [41] . Much research is currently aimed at generating strategies for targeting different STATs, and a significant amount of attention is being paid to developing JAK inhibitors aimed at use in the area of transplantation and immunosuppressive treatments. A selective JAK3 inhibitor was recently generated, which may represent a novel class of effective immunosuppressants since it has proved effective in transplant rejection in animal models [43] . The JAK/STAT pathway is but one of the stress/ stretch-activated signaling pathways which have been identified in cardiomyocytes exposed to diverse demands [44] . Other pathways include G-proteins (guanine nucleotidebinding proteins), MAPK (mitogen-activated protein kinases), PKC (protein kinase C), ERK (extracellular signal-regulated protein kinases), JNK (c-Jun NH2-terminal kinases), the protein phosphatase calcinuerin, intracellular Ca 2+ regulation, and a number of autocrine and paracrine factors [45] . Not only do these stress-activated pathways initiate and maintain the phenotypical cardiac alterations, but they have also been implicated in affecting the cardiomyocytes in deciding whether to survive or undergo apoptosis (Fig. 1) [45] . Consequently further research aimed at exploring the function of these individual proteins might pave the way for novel therapeutic opportunities in treatment of heart disease.
Cytokines and their implications in heart disease
It is well-established that cardiac myocytes and fibroblasts produce cytokines locally [9] . Studies have shown that various pro-inflammatory markers, including the cytokines TNF-α (tumor necrosis factor alpha), IL-1 and IL-6 (interleukin 1 and 6 respectively), are activated in different types of pathophysiologic processes involving the heart (Fig. 1 ) [46, 47] . TNF-α has furthermore been implicated in regulation of vascular functions related to atherosclerotic plaque stability and may as such be partially responsible for plaque rupture [48] . Similarly, IL-6 promotes expression of ICAM-1 (intercellular adhesion molecule 1) and synthesis of CRP (Creactive protein), with potential significant implications in atherosclerotic plaque formation and progression [49] . Accumulating evidence indicates that proinflammatory cytokines negatively influence the inotrophic state of the heart as well as induce hypertrophy and promote apoptosis or fibrosis, thereby actively contributing to myocardial remodeling and thus development of heart failure [46] . TNFα is one of the proinflammatory cytokines that has been implicated in cardiac dysfunction [50] and recent studies have shown that NF-κB activation and increased TNFα production may play a central role in cardiac injury due to intracellular Ca 2+ overload [51] . In addition, myocyte apoptosis can be triggered by TNFα and its second messenger sphingosine, which consequently is partially responsible for the cardiac cachexia seen in heart failure patients [52] ; just as cytokineinduced depression of myocardial contractility reportedly results from production of sphingosine due to interference with myocardial Ca 2+ handling (Fig. 1 ) [47] . TNFα and IL1β appear to act both separately as well as synergistically towards depressing myocardial function, and it is likely that sphingosine also participates in this synergistic signaling leading to injurious effects on the heart [53] . Studies on feline cardiomyocytes have additionally shown that agents which modulate sphingosine production also minimize cardiodepression thus providing a potential therapeutic benefit in clinical conditions of myocardial inflammatory injury [54] . Paradoxically, recent studies have shown that low doses of TNFα can induce cardiac preconditioning, furthermore concluding that there is evidence for a production and role of free radicals in TNFα-induced cardioprotection [55] . IL-6 is another proinflammatory cytokine involved in cardiodepression and plasma levels of IL-6 are typically elevated in heart failure patients and inversely correlated to left ventricular function [56] . In addition, growing experimental evidence suggests a role for IL-6 in mediating part of the deleterious cardiovascular modifications observed in heart failure [56] . It has furthermore been suggested that IL-6 is involved in a paracrine interaction between cardiac myocytes and fibroblasts resulting in cardiac fibroblasts enhancing myocyte hypertrophy and cardiac myocytes regulating fibroblast adhesion and proliferation [9] . Numerous endogenous mechanisms exist for negatively regulating cytokine signaling and whether novel therapies can be devised that exploit these mechanisms remains to be further elucidated [43] . Recent multi-center trials with the anti-TNF-alpha compounds etanercept (i.e. RENEWAL trial) and infliximab (i.e. AT-TACH trial) have questioned the beneficial effect of targeting single cytokines [57, 58] . Both trials concurred that no safety issues was seen with regards to infliximab or etanercept at lower dosages, but pointed out that high doses of anti-TNF therapy may be without effect in heart failure patients [59] . Other smaller trials (e.g. ENBREL) have, on the other hand, reported dose-dependent improvement in heart function with etanercept treatment [60] , whereas adverse effects including toxicities secondary to TNF-alpha blocker therapy have been reported by others [13, 61] . Despite the somewhat disappointing and rather controversial results thus far, the "cytokine hypothesis" remains an interesting concept in development of novel efficacious therapies for heart failure patients. The studies accentuate the complexity of the cytokine network, however, and have partially caused a redirection of the focus towards more general immunomodulating treatment modalities [62] . Interestingly, nevertheless, the pro-inflammatory cytokines are frequently induced even before classical neurohormones such as angiotensin II and noradrenaline in patients with chronic heart failure, and so the overactive immune system still remains a promising target for therapeutical interventions aimed at slowing down cardiac disease progression. On the other extreme, a number of cytokines, including G-CSF (granulocyte colony stimulating factor), leukemia inhibitory factor and EPO (erythropoietin) have proven to have beneficial effects on cardiac remodeling after infarction [40, 63] . Furthermore endogenous anti-inflammatory cytokines such as IL-2 and IL-10 have proved to protect the myocardium against injury induced by ischemia and reperfusion [64] . It has been shown that G-CSF activates the JAK/STAT pathway in cardiomyocytes thus protecting against cardiac remodeling by reducing apoptosis post infarction [40] . Rapid activation of potassium channels and protein kinases by EPO reportedly represents a central new mechanism for increased cardioprotection. Another recent study suggests that EPO has cardioprotective effects by preventing cardiomyocyte apoptosis [63] . EPO seems to instigate the immediate protection of the heart through multiple signal transduction pathways, among which the JAK/STAT is one of them [65] . Additional experiments have revealed that the rapid cardioprotective effect of EPO is associated with ATP preservation in the ischemic myocardium [66] . In view of the existing knowledge on the biological effects of cytokines on the heart, anti-cytokine therapy is likely to provide a new direction for management of heart failure. Even though a cytokine-mediated response initially may be beneficial, it might become deleterious when sustained. In addition, the same therapeutic approach has the potential of acting differently in a given patient depending on the disease state. Consequently future therapies likely need to aim at intracellular goals to inactivate signaling systems responsible for injurious effect in cardiac disease and heart failure [67] .
Cardiac antimicrobial peptides
Antimicrobial peptides (AMPs) are "multi-tasking natural antibiotics" and ancient molecules of innate immunity with functions extending far beyond that of simple antibioticsincluding anti-tumor and mitogenic activity, as well as immunomodulation and signal transduction characteristics [68] . The term antimicrobial is used because these peptides have extraordinary broad spectra of activity, including an ability to kill or neutralize Gram-negative and Gram-positive bacteria, fungi, yeast, cancer cells and some enveloped viruses [69] . The overall effectiveness of an innate immunity based host defense is shown by the clearly successful survival of plants and invertebrates, organisms which completely lack adaptive immunity. Defensins (including α-, β-and θ-defensins) and cathelicidins constitute the two major groups of AMPs in the majority of mammalian species [70] . Mammalian defensins are endogenous cysteine-rich peptide molecules classically produced by epithelial cells of the external and internal surfaces or by circulating cells, including granulocytes and macrophages. β-defensins are small (3.5-4.5 kDa) highly basic cationic peptides, structurally defined by a conserved cysteine-rich motif forming three disulphide bonds, which stabilize a β-sheet formation [71] . Their folding pattern is determined by the amphipathicity of these molecules, which is also believed to govern their antimicrobial effect. The mechanism of action is thought to rely on permeabilization of the microbial membrane and lysis of invading organisms, which is explained in theory by the ShaiMatsuzaki-Huang (SMH) model [72] . Epithelial β-defensins consequently represent a rapidly mobilized local defense against microbial intruders at the epithelial and mucosal surfaces, and several studies have shown induction of these defensins at sites of inflammation, injury, infection as well as other types of disease processes [73] . β-defensins are either constitutive or inducible, and their production can be elicited by ligands such as bacterial LPS through TLRs using the NFkB pathway ( Fig. 2A) [74] . Other pathways, including MAPK and JAK/STAT signaling, seem to be involved in β-defensin regulation [75] . β-Defensins have recently been identified in what may be considered as non-traditional tissue such as the heart; including HBD-3 (human beta-defensin 3) expression in adult human heart [76] , pBD1 (porcine beta-defensin 1) in pigs [77] , eBD1 (equine beta-defensin 1) in the horse [78] , Defb1 (murine beta-defensin 1) in mice [79] , and rBD1 (rat betadefensin 1) in the rat [73] . Our laboratory has furthermore recently documented that at least seven different betadefensins (i.e. rBD1/3/10/11/15/18 and 33) are expressed in the adult rat heart (unpublished data). These findings suggest that AMPs might participate as effector molecules of the innate immune system in the heart as in other types of tissue, but information on cardiac AMPs is still sparse and further research is needed to elucidate the actual role played by AMPs in heart disease and health.
The heart as an immunological organ
The heart possesses a gene-encoded intrinsic or innate stress system, which is activated in response to different types of injury (Fig. 3) [80] . This local innate stress response plays a key role in instigating and coordinating homeostatic responses in the heart, while the released inflammatory mediators at the same time possess the potential of producing cardiac decompensation if expressed at sufficiently high concentrations [80] . The quintessential feature of this innate immune system is that it serves as an immediate warning system thus constituting a first-line-of-defense allowing the host to discriminate self from non-self [80] . The "Danger Model of Immunity" suggests that cell damage rather than foreignness is what prompts an immune response (Fig. 3 ) [81] , and current research also suggests that chronic heart failure in fact is a state of chronic inflammation, thus stressing the importance of a functionally intact innate immune system in the heart. Pro-inflammatory cytokines appear to play a central role in the orchestration and timing of the intrinsic cardiac stress response providing instantaneous anti-apoptotic cytoprotective signals, as well as delayed signals facilitating tissue repair and/or remodeling. The protective response may occur at the cost of unwanted injurious effects occurring when cytokines are elaborately expressed for sustained time intervals or at pathologic/supra-physiologic levels contributing to cardiac remodeling through different mechanisms involving cardiomyocytes as well as noncardiomyocytes [80] . As in the case with TNFα, NF-κB and AP1 (activator protein 1) have been suggested as potential therapeutic targets, since these proteins are activated in heart failure patients [16] . Not only has NF-κB proved to play a key role in muscle wasting and cardiac cachexia in heart disease, but its activation also seems to play a role in proliferation of vascular smooth muscle cells and intimal hyperplasia in atherosclerosis [82] . Furthermore, NF-κB is both necessary and sufficient to elicit a hypertrophic response in isolated rat cardiomyocytes [83] , and TNFα-induced hypertrophy is reported as being dependent on NF-κB activation [84] . The activities of NF-κB-dependent genes can in fact explain many of the actions of TNFα on the heart [27] . Results from studies involving transgenic mice show that TNFα over-expression can cause development of severe dilated cardiomyopathy with rapid progression to heart failure [85] . Interestingly, the cardiac-specific TNFα expression in these transgenic mice can lead to not only heart failure through activation of pro-apoptotic signaling pathways, but also cardioprotection through activation of antiapoptotic proteins [86] . NF-κB-signaling is therefore likely a mixture of pro-and anti-apoptotic activity, as well as other effects such as inflammation and infiltration, as well as effects on Ca 2+ handling and NO (nitric oxide) production etc. [27] . Moreover, cross-talk seems to exist between NF-κB and other signaling pathways [27] . Apoptosis has been implicated in different aspects of cardiac pathology, including cardiomyopathy, myocardial infarction and heart failure [87] , thus making regulation of pro-and anti-apoptotic signaling a quite central topic when addressing heart disease. Apoptosis and necrosis differentially contribute to myocardial injury. Still, the extent to which apoptosis versus necrosis is mechanistically accountable for cell death in the intact heart post infarction/reperfusion is somewhat controversial [27] . Apoptosis appears to be the predominant mechanism for at least the first 24 h post infarction, whereas necrosis seems to be more predominant in the developing infarct [88] . Modification of TLR expression may prove another important therapeutic target. TLR1, 2 and 4 expressions are all enhanced in human atherosclerotic plaques [89] , and studies in knock-out mice have shown that inhibitors of TLR4 may be helpful in treatment of atherosclerosis [90] . Studies have shown that inhibition of TLR2 may be advantageous after myocardial infarction since this TLR seems to play an important role in ventricular remodeling [91] . Much attention has clearly been paid to non-pathogenic insult affecting the heart, while infections with viruses, protozoa, fungi or bacteria clearly also can be associated with heart disease and thus responsible for eliciting an innate immune response and inflammation. The most common virus infection type identified in the human heart are due to the Coxsackie B group viruses, which can be detected in up to 50% of patients with dilated cardiomyopathy [92] -work which, however, remains controversial. As such one of the main etiological factors in DCM is persistence of cardiotrophic viruses (including enterovirus, adenovirus, human cytomegalovirus, parvovirus B19, and influenza virus). The significance of viral injury and inflammation in the etiology of certain cardiomyopathies is further recognized by the most recent WHO/WHF definition of inflammatory cardiomyopathy (DCMi) as a distinct entity adding to the already existing five major forms of cardiomyopathies [93, 94] . Naturally occurring, as well as experimentally induced, cardiovascular disorders have been associated with a range of different causative pathogens [95] . It is worth keeping in mind that cardiovascular organs may also become "casualties" of inflammatory processes that have a focus outside the heart [2] . In sepsis, TNFα has also been implicated as a key factor in development of myocardial dysfunction [24] . The canine and human cardiovascular profile is remarkably similar in sepsis, and the sphingomyelin pathway is believed to play a central role in TNFα-induced myocardial depression in both species. In addition, these highly specialized immune processes are not surprisingly of outmost interest in thoracic surgery, as a systemic inflammatory response syndrome (SIRS) due to cellular and humoral defense reactions are activated in cardiac surgery using cardiopulmonary bypass [96] . A line of research has focused on the innate immune response associated with open heart surgery and cardiac transplantation. One study found that activation of an innate immune response through TLR4 contributes to development of chronic rejection after heart transplantation Fig. 3 . Schematic danger model of intrinsic cardiac immunity illustrating factors which may initiate an innate immune response within the heart, leading to activation of intrinsic signaling pathways and production of certain immune mediators, which may have either protective or deleterious effects -ultimately resulting in cardiac stabilization or failure. Abbreviations -AMPs = antimicrobial peptides; JAK/STAT = Janus-kinase/signal transducer and activator of transcription; NF-κB = nuclear factor kappa B; TLRs = toll-like receptors. [97] . In children with congenital heart disease, cardiopulmonary bypass elicits a prominent innate immune response, and cardiac operations are associated with increased oxidative stress, leukocyte activation and increased production of pro-and anti-inflammatory cytokines [98] . TLR2 and 4 are suggested as putative signaling receptors for heat shock proteins (HSP) in mediating synthesis of inflammatory cytokines in cardiac surgery [99] . In conclusion, evidence is rapidly accumulating that the effector-molecules and signaling pathways of the innate immune response have a marked impact on the heart in different types of cardiac diseases. Ultimately, the myocardium's ability to adapt to environmental stress determines if it will maintain health or decompensate and fail [80] . Still, further research aimed at elucidating the molecular mechanisms behind potential injurious and protective effects caused by the innate immune response is pivotal toward gaining a better understanding of many types of cardiovascular pathology.
Summary
Inflammation underlies the pathogenesis of a range of the most common cardiovascular diseases. Recent development and use of genetically manipulated murine models such as transgenic/knock-out mice have created an opportunity to pinpoint specific signaling pathways underlying heart disease as well as evaluate therapeutic strategies of candidates for clinical development. When formulating treatment strategies in inflammatory processes in any organ it is essential to understand tissue-specific pathways that may either intensify or dampen cells and mediators of the inflammatory system [100] . It is important to recognize that amplification and/or damping of the inflammatory reaction is likely to vary between organs, and that the primary cellular composition of an organ, as well as the matrix and mediators released by specialized cells will govern the overall inflammatory reaction [100] . Immunomodulatory therapy has emerged as a possible new treatment modality in CHF, as traditional cardiovascular drugs seem to have little if any effect on the overall cytokine network. Selective gene targeting to identify which PRRs play a central role in the heart secondary to injury will likely be one obvious area for future discovery. Overall, relatively little is still known about how the innate immunity response is modulated in the heart and it is therefore most likely that the learning curve will remain rather steep in the most immediate future [80] . In all considerations it is pivotal to keep in mind the "Janus Face" of innate immunity and inflammation as a system that aims to heal but holds the capacity to destroy.
